Investigating retatrutide for Type 2 Diabetes with kidney issues
Official title: A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor
Run by Eli Lilly and Company · NCT06297603 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests if a new medication called retatrutide can help people with Type 2 Diabetes and kidney problems better control their blood sugar compared to a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 320 (estimated) |
| Sponsor | Eli Lilly and Company Industry-sponsored |
| Locations | 80 sites (Huntsville, Alabama and 79 other locations) |
| Trial ID | NCT06297603 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with Type 2 Diabetes, moderate to severe renal impairment, and inadequate glycemic control on their current diabetes regimen.
✕Probably not a fit
Patients with Type 1 Diabetes or those with a history of severe hypoglycemia or unstable renal disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the efficacy and safety of retatrutide compared to a placebo in individuals with Type 2 Diabetes who also have moderate or severe renal impairment and are not achieving adequate glycemic control on basal insulin, with or without additional medications like metformin or SGLT2 inhibitors. The trial will last approximately 14 months and may involve up to 22 visits for participants. It focuses on patients who have been on stable diabetes treatment prior to screening and have specific HbA1c levels.
Why it matters
Potential benefit: If successful, this treatment could significantly improve glycemic control in patients with Type 2 Diabetes and renal impairment.
How similar studies have gone: Other studies have shown promise in treating Type 2 Diabetes with similar approaches, but this specific combination is being explored for the first time.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have Type 2 Diabetes (T2D) * Have HbA1c ≥7.0% (53 millimoles per mole (mmol/mol)) to ≤10.5% (91 mmol/mol) * Have moderate or severe renal impairment * Have been on the following stable diabetes treatment during 90 days prior to screening * basal insulin (≥20 International Units (IU)/day) with or without * metformin and/or SGLT2 inhibitor * Are of stable weight for at least 90 days prior to screening * Have a Body Mass Index (BMI) ≥23.0 kilograms per meter squared (kg/m2) Exclusion Criteria: * Have Type 1 Diabetes (T1D) * Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have a history of unstable or rapidly progressing renal disease * Have a prior or planned surgical treatment for obesity * Have New York Heart Association Functional Classification III or IV congestive heart failure * Have had acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening * Have a known clinically significant gastric emptying abnormality * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years * Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2. * Have any lifetime history of a suicide attempt * Had chronic or acute pancreatitis * Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening
Where it's running
-
Nephrology Consultants
Huntsville, Alabama, United States Recruiting -
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, United States Recruiting -
Kidney & Hypertension Center - Apple Valley
Apple Valley, California, United States Recruiting -
Hope Clinical Research, Inc.
Canoga Park, California, United States Recruiting -
Neighborhood Healthcare Institute of Health
Escondido, California, United States Recruiting -
EndoTrials Center for Clinical Research
La Mesa, California, United States Recruiting
Show 44 more locations
-
UCLA South Bay Endocrinology
Torrance, California, United States Recruiting -
Northeast Research Institute (NERI)
Fleming Island, Florida, United States Recruiting -
Encore Medical Research - Weston
Weston, Florida, United States Recruiting -
Orita Clinical Research
Decatur, Georgia, United States Recruiting -
Care Research
Idaho Falls, Idaho, United States Recruiting -
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, United States Recruiting -
Billings Clinic
Billings, Montana, United States Recruiting -
Excel Clinical Research, LLC
Las Vegas, Nevada, United States Recruiting -
Albany Medical College, Division of Community Endocrinology
Albany, New York, United States Recruiting -
NYC Research INC
Long Island City, New York, United States Recruiting -
Research Foundation of SUNY - University of Buffalo
Williamsville, New York, United States Recruiting -
University of North Carolina Medical Center
Chapel Hill, North Carolina, United States Recruiting -
Lucas Research, Inc.
Hickory, North Carolina, United States Recruiting -
Cleveland Clinic
Cleveland, Ohio, United States Recruiting -
Central States Research
Tulsa, Oklahoma, United States Recruiting -
Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
Pittsburgh, Pennsylvania, United States Recruiting -
AM Diabetes & Endocrinology Center
Bartlett, Tennessee, United States Recruiting -
Velocity Clinical Research, Dallas
Dallas, Texas, United States Recruiting -
Prime Revival Research Institute, LLC
Flower Mound, Texas, United States Recruiting -
Juno Research
Houston, Texas, United States Recruiting -
PlanIt Research, PLLC
Houston, Texas, United States Recruiting -
Southern Endocrinology Associates
Mesquite, Texas, United States Recruiting -
Texas Valley Clinical Research
Weslaco, Texas, United States Recruiting -
Diabetes & Endocrine Treatment Specialists
Sandy, Utah, United States Recruiting -
Cedic
Caba, Buenos Aires, Argentina Recruiting -
CIMeL
Lanus, Buenos Aires, Argentina Recruiting -
Centro de Investigaciones Médicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina Recruiting -
DIM Clínica Privada
Ramos Mejía, Buenos Aires, Argentina Recruiting -
Investigaciones Medicas Imoba Srl
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina Recruiting -
Ciprec
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina Recruiting -
Centro Médico Viamonte
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina Recruiting -
Mautalen Salud e Investigación
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina Recruiting -
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Ciudad Autonoma de Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina Recruiting -
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, Santa Fe, Argentina Recruiting -
INECO Neurociencias Oroño
Rosario, Santa Fe, Argentina Recruiting -
Instituto Médico Catamarca IMEC
Rosario, Santa Fe, Argentina Recruiting -
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica
Rosario, Santa Fe, Argentina Recruiting -
Instituto de Investigaciones Clinicas Rosario
Rosario, Santa Fe, Argentina Recruiting -
Ciprec
Buenos Aires, Argentina Recruiting -
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aires, Argentina Recruiting -
Centro Diabetológico Dr. Waitman
Córdoba, Argentina Recruiting -
Centro Médico Colón
Córdoba, Argentina Recruiting -
Centro de Endocrinologia Alcantara Gonzalez
Bayamon, Puerto Rico Recruiting -
Isis Clinical Research Center
Guaynabo, Puerto Rico Recruiting
+30 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Email: clinical_inquiry_hub@lilly.com
- Phone: 1-317-615-4559
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acute Blood Flow Restriction Walking in Type 2 Diabetes
This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.
-
Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin
This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses
This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.
-
Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar
This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.
-
Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes
This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.